Summary for Elevance Health, Inc. (NYSE: ELV)
Positive Sentiment:
Bernstein sticks to its buy rating for Elevance Health.
Bernstein Sticks to Its Buy Rating for Elevance Health (ELV)
Positive Sentiment:
Wells Fargo maintains a buy rating on Elevance Health and sets a $478 price target.
Wells Fargo Maintains a Buy on Elevance Health (ELV), Sets a $478 PT
Positive Sentiment:
Bernstein reaffirms its buy rating on Elevance Health and raises its price target to $585.
Bernstein Maintains a Buy on Elevance Health (ELV), Sets a $585 PT
Neutral Sentiment:
Elevance and Blue Cross Blue Shield have filed suit against LifeX Research over alleged ‘fake’ Anthem health benefits, underscoring the company’s efforts to protect its brand and member trust.
Elevance, Blue Cross Blue Shield sue LifeX Research over 'fake' Anthem health benefits
Negative Sentiment:
Multiple securities class action lawsuits have been filed against Elevance Health by firms including Rosen Law Firm, Bragar Eagel & Squire, Faruqi & Faruqi, and others, urging investors with losses during April 18–October 16, 2024 to contact counsel before the July 11 lead plaintiff deadline.
ELV Deadline: ELV Investors with Losses in Excess of $100K Have Opportunity to Lead Elevance Health, Inc. Securities Fraud Lawsuit
Negative Sentiment:
Analysts at Zacks forecast a Q2 earnings decline for Elevance Health, suggesting the upcoming report may miss consensus estimates.
Earnings Preview: Elevance Health (ELV) Q2 Earnings Expected to Decline
Posted 1+ days ago
AI Generated. May Contain Errors.